Skip to main content

With artificial bone marrow, scientists aim to decode blood disease

Bone marrow is like the offensive line of the immune system — it’s an essential part of the team but doesn’t always gets the recognition. By pumping out hundreds of billions of blood cells every day, bone marrow helps us fend off disease and is essential to a healthy human body.

To better understand how marrow fortifies us against disease — and to potentially help develop better therapies for diseases like leukemia — researchers have sought to develop artificial bone marrow that functions like the real thing. The problem is, living blood cells reside and multiply in a special environment, called the hematopoietic niche, which scientists have so far failed to replicate.

Recommended Videos

But now, researchers from the University of Basel and ETH Zurich have engineered an artificial bone marrow that mimics the natural kinds, offering a key to better understand how blood forms and how blood diseases can be treated.

“This 3D engineered tissue is established and maintained in a bioreactor system,” Ivan Martin, a professor of biomedicine at the University of Basel who worked on the project, told Digital Trends. “It partially recapitulates the structure, composition, and organization of the native bone marrow microenvironment … but also its main function, which is the replication and differentiation in more mature cells.”

Martin and his colleagues used a ceramic bonelike scaffold, which they combined with living cells in a bioreactor, mixing the synthetic and organic components together.

Within that artificial system, cells are able to multiply over the course of several days — not as long as natural bone marrow, but degrees better than previous synthetic models. Rather than immediate medical applications, the researchers hope their technique leads to more sophisticated, tailor-made marrow models, which can assist in drug screening.

“More than a direct medical demand, the fields of hematology and tissue engineering lacked a model close enough to sustain reasonable comparison with the in vivo human bone marrow microenvironment,” Matin said. “Indeed, research has limited possibilities to access information from human specimens and the human hematopoietic niche has remained rather inaccessible to experimental manipulation and optical observation.”

Moving forward, Martin and his team hope to use this system to study blood disorders, particularly the conditions within which these conditions first arise.

A paper detailing their research was published this week in the journal Proceeding of the National Academy of Sciences.

Dyllan Furness
Former Digital Trends Contributor
Dyllan Furness is a freelance writer from Florida. He covers strange science and emerging tech for Digital Trends, focusing…
Rivian offers $3,000 off select EVs to gasoline, hybrid vehicle drivers
Second-Gen Rivian R1S on a road

Early November typically kicks off the run-up to the Black Friday sales season, and this year, Rivian is betting it’s the perfect time to lure gasoline drivers toward its EVs.
If you own or lease a vehicle that runs on gasoline, which means even a hybrid vehicle, Rivian is ready to give you $3,000 off the purchase of one of its select fully electric vehicles -- no trade-in required.
The offer from the Irvine, California-based automaker extends to customers in the U.S. and Canada and runs through November 30, 2024. The program applies to Rivian 2025 R1S or R1T Dual Large, Dual Max, or Tri Max models purchased from R1 Shop.
Rivian’s new All-Electric Upgrade offer marks a change from a previous trade-in program that ran between April and June. There, owners of select 2018 gas-powered vehicles from Ford, Toyota, Jeep, Audi, and BMW could trade in their vehicle and receive up to $5,000 toward the purchase of a new Rivian.
This time, buyers of the R1S or R1T Rivian just need to provide proof of ownership or lease of a gas-powered or hybrid vehicle to receive the discount when they place their order.
Rivian is not going to be the only car maker offering discounts in November. Sluggish car sales from giants such as Stellantis and rising inventories of new cars due to improving supply chains suggest automakers and dealerships will be competing to offer big incentives through the year's end.
This follows several years of constrained supply following the COVID pandemic, which led to higher prices in North America.
According to CarEdge Insights, average selling prices for cars remain above what would be called affordable. But prices should continue improving along with rising inventories.
Stellantis brands are entering November with the most inventory, followed by GM and Ford, according to CarEdge. Toyota and Honda, meanwhile, have the least inventory, meaning they probably won’t be under pressure to offer big incentives.

Read more
AT&T, Voltpost bring internet connectivity to EV charging lampposts
att voltpost streetlight charging newlabdetroit 63

Move over, Supercharger network.

EV charging networks have been fast expanding across U.S. roads and highways over the past year, led by the likes of Electrify America, Tesla, and Chargescape, to name a few.

Read more
Volvo’s much-anticipated EX30 EV to reach U.S. before year end
Front three quarter view of the 2025 Volvo EX30.

Volvo is switching gears again, this time to accelerate deliveries of its much-anticipated EX30 subcompact electric SUV so that it reaches the U.S. before the end of 2024.

The Swedish automaker last summer had postponed the U.S. launch of the EX30 to 2025, citing “changes in the global automotive landscape." The move followed the Biden administration’s 100% import tariff on electric vehicles made in China.

Read more